The DOI matches its Crossref record; 292 of the 292 references it cites were found in a registry or an index.
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Abstract
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer focuses on systemic therapy options for the treatment of metastatic colorectal cancer (mCRC), because important updates have recently been made to this section. These updates include recommendations for first-line use of checkpoint inhibitors for mCRC, that is deficient mismatch repair/microsatellite instability-high, recommendations related to the use of biosimilars, and expanded recommendations for biomarker testing. The systemic therapy recommendations now include targeted therapy options for patients with mCRC that is HER2-amplified, or BRAF V600E mutation–positive. Treatment and management of nonmetastatic or resectable/ablatable metastatic disease are discussed in the complete version of the NCCN Guidelines for Colon Cancer available at NCCN.org. Additional topics covered in the complete version include risk assessment, staging, pathology, posttreatment surveillance, and survivorship.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Colorectal cancer statistics, 2020
Siegel, R. L., Miller, K. D., Goding Sauer, A., Fedewa, S. A., Butterly, L. F., Anderson, J. C., Cercek, A., Smith, R. A., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21601 · Cited by 4,880
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
Self-citationWild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Self-citationTournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836
Self-citationEfficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30445-9 · Cited by 2,552
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
Self-citationPanitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079
Self-citationVan Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Nordlinger, B., Sorbye, H., Glimelius, B., Poston, G. J., Schlag, P. M., Rougier, P., Bechstein, W. O., Primrose, J. N., Walpole, E. T., Finch-Jones, M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60455-9 · Cited by 1,937
Cetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Van Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882
Douillard, J.-Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4860 · Cited by 1,809
Doebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., Blakely, C. M., Seto, T., Cho, B. C., Tosi, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30691-6 · Cited by 1,790
Self-citationHeinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740
Kabbinavar, F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Lieberman, G., Griffing, S., & Bergsland, E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,716
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Self-citationBokemeyer, C., Bondarenko, I., Makhson, A., Hartmann, J. T., Aparicio, J., de Braud, F., Donea, S., Ludwig, H., Schuch, G., Stroh, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8397 · Cited by 1,636
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Cetuximab in the treatment of colorectal cancer.
Goldberg, R. M., Venook, A. P., & Schilsky, R. L. (2004) · PubMed · Cited by 1,518
Self-citationEncorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491
Adam, R., Delvart, V., Pascal, G., Valeanu, A., Castaing, D., Azoulay, D., Giacchetti, S., Paule, B., Kunstlinger, F., Ghémard, O., et al. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000141198.92114.f6 · Cited by 1,480
Trends in Long-Term Survival Following Liver Resection for Hepatic Colorectal Metastases
Choti, M. A., Sitzmann, J. V., Tiburi, M. F., Sumetchotimetha, W., Rangsin, R., Schulick, R. D., Lillemoe, K. D., Yeo, C. J., & Cameron, J. L. (2002) · Annals of Surgery · doi:10.1097/00000658-200206000-00002 · Cited by 1,454
Lièvre, A., Bachet, J.-B., Boige, V., Cayre, A., Le Corre, D., Buc, E., Ychou, M., Bouché, O., Landi, B., Louvet, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5906 · Cited by 1,444
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414325 · Cited by 1,431
Van Cutsem, E., Tabernero, J., Lakomy, R., Prenen, H., Prausová, J., Macarulla, T., Ruff, P., van Hazel, G. A., Moiseyenko, V., Ferry, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8201 · Cited by 1,402
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Tol, J., Koopman, M., Cats, A., Rodenburg, C. J., Creemers, G. J. M., Schrama, J. G., Erdkamp, F. L. G., Vos, A. H., van Groeningen, C. J., Sinnige, H. A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808268 · Cited by 1,341
Nordlinger, B., Sorbye, H., Glimelius, B., Poston, G. J., Schlag, P. M., Rougier, P., Bechstein, W. O., Primrose, J. N., Walpole, E. T., Finch-Jones, M., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70447-9 · Cited by 1,306
Liver resection for colorectal metastases.
Fong, Y., Cohen, A. M., Fortner, J. G., Enker, W. E., Turnbull, A. D., Coit, D. G., Marrero, A. M., Prasad, M., Blumgart, L. H., & Brennan, M. F. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.938 · Cited by 1,284
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259
Falcone, A., Ricci, S., Brunetti, I., Pfanner, E., Allegrini, G., Barbara, C., Crinò, L., Benedetti, G., Evangelista, W., Fanchini, L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0928 · Cited by 1,241
Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
Naidoo, J., Wang, X., Woo, K. M., Iyriboz, T., Halpenny, D., Cunningham, J., Chaft, J. E., Segal, N. H., Callahan, M. K., Lesokhin, A. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.2005 · Cited by 1,215
Bennouna, J., Sastre, J., Arnold, D., Österlund, P., Greil, R., Van Cutsem, E., von Moos, R., Viéitez, J. M., Bouché, O., Borg, C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70477-1 · Cited by 1,166
Roth, A. D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3452 · Cited by 1,158
Khambata-Ford, S., Garrett, C. R., Meropol, N. J., Basik, M., Harbison, C. T., Wu, S., Wong, T. W., Huang, X., Takimoto, C. H., Godwin, A. K., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5437 · Cited by 1,125
Self-citationPawlik, T. M., Scoggins, C. R., Zorzi, D., Abdalla, E. K., Andres, A., Eng, C., Curley, S. A., Loyer, E. M., Muratore, A., Mentha, G., et al. (2005) · Annals of Surgery · doi:10.1097/01.sla.0000160703.75808.7d · Cited by 1,101
Cremolini, C., Loupakis, F., Antoniotti, C., Lupi, C., Sensi, E., Lonardi, S., Mezi, S., Tomasello, G., Ronzoni, M., Zaniboni, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00122-9 · Cited by 1,092
Bailey, C. E., Hu, C.-Y., You, Y. N., Bednarski, B. K., Rodriguez-Bigas, M. A., Skibber, J. M., Cantor, S. B., & Chang, G. J. (2015) · JAMA Surgery · doi:10.1001/jamasurg.2014.1756 · Cited by 1,077
Self-citationGrothey, A., Sargent, D., Goldberg, R. M., & Schmoll, H.-J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.037 · Cited by 1,070
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
Loupakis, F., Cremolini, C., Masi, G., Lonardi, S., Zagonel, V., Salvatore, L., Cortesi, E., Tomasello, G., Ronzoni, M., Spadi, R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403108 · Cited by 1,062
Van Cutsem, E., Twelves, C., Cassidy, J., Allman, D., Bajetta, E., Boyer, M., Bugat, R., Findlay, M., Frings, S., Jahn, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.21.4097 · Cited by 1,032
Hong, D. S., DuBois, S. G., Kummar, S., Farago, A. F., Albert, C. M., Rohrberg, K. S., van Tilburg, C. M., Nagasubramanian, R., Berlin, J. D., Federman, N., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30856-3 · Cited by 1,028
Sartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., Zagonel, V., Leone, F., Depetris, I., Martinelli, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00150-9 · Cited by 1,016
Peeters, M., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., Punt, C. J. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6055 · Cited by 1,005
Le, D. T., Kim, T. W., Van Cutsem, E., Geva, R., Jäger, D., Hara, H., Burge, M., O’Neil, B., Kavan, P., Yoshino, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02107 · Cited by 1,005
Rougier, P., Van Cutsem, E., Bajetta, E., Niederle, N., Possinger, K., Labianca, R., Navarro, M., Morant, R., Bleiberg, H., Wils, J., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03085-2 · Cited by 992
Innocenti, F., Undevia, S. D., Iyer, L., Xian Chen, P., Das, S., Kocherginsky, M., Karrison, T., Janisch, L., Ramírez, J., Rudin, C. M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.173 · Cited by 964
Maughan, T. S., Adams, R. A., Smith, C. G., Meade, A. M., Seymour, M. T., Wilson, R. H., Idziaszczyk, S., Harris, R., Fisher, D., Kenny, S. L., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60613-2 · Cited by 960
Tabernero, J., Yoshino, T., Cohn, A. L., Obermannova, R., Bodoky, G., Garcia-Carbonero, R., Ciuleanu, T.-E., Portnoy, D. C., Van Cutsem, E., Grothey, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70127-0 · Cited by 952
Sobrero, A. F., Maurel, J., Fehrenbacher, L., Scheithauer, W., Abubakr, Y. A., Lutz, M. P., Vega-Villegas, M. E., Eng, C., Steinhauer, E. U., Prausova, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1193 · Cited by 946
Kabbinavar, F. F., Schulz, J., McCleod, M., Patel, T., Hamm, J. T., Hecht, J. R., Mass, R., Perrou, B., Nelson, B., & Novotny, W. F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.112 · Cited by 929
Self-citationVenook, A. P., Niedzwiecki, D., Lenz, H.-J., Innocenti, F., Fruth, B., Meyerhardt, J. A., Schrag, D., Greene, C., O'Neil, B. H., Atkins, J. N., et al. (2017) · JAMA · doi:10.1001/jama.2017.7105 · Cited by 898
Self-citationCassidy, J., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9898 · Cited by 862
Self-citationClinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer
Yaeger, R., Chatila, W. K., Lipsyc, M. D., Hechtman, J. F., Cercek, A., Sanchez-Vega, F., Jayakumaran, G., Middha, S., Zehir, A., Donoghue, M. T. A., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.12.004 · Cited by 858
Self-citationHecht, J. R., Mitchell, E., Chidiac, T., Scroggin, C., Hagenstad, C., Spigel, D., Marshall, J., Cohn, A., McCollum, D., Stella, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8135 · Cited by 850
Self-citationArnold, D., Lueza, B., Douillard, J.-Y., Peeters, M., Lenz, H.-J., Venook, A., Heinemann, V., Van Cutsem, E., Pignon, J.-P., Tabernero, J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx175 · Cited by 838
Self-citationDe Roock, W., Piessevaux, H., De Schutter, J., Janssens, M., De Hertogh, G., Personeni, N., Biesmans, B., Van Laethem, J.-L., Peeters, M., Humblet, Y., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm496 · Cited by 827
Li, J., Qin, S., Xu, R., Yau, T. C. C., Ma, B., Pan, H., Xu, J., Bai, Y., Chi, Y., Wang, L., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70156-7 · Cited by 813
Tournigand, C., Cervantes, A., Figer, A., Lledo, G., Flesch, M., Buyse, M., Mineur, L., Carola, E., Etienne, P.-L., Rivera, F., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0106 · Cited by 805
Colucci, G., Gebbia, V., Paoletti, G., Giuliani, F., Caruso, M., Gebbia, N., Cartenì, G., Agostara, B., Pezzella, G., Manzione, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.113 · Cited by 779
Venderbosch, S., Nagtegaal, I. D., Maughan, T. S., Smith, C. G., Cheadle, J. P., Fisher, D., Kaplan, R., Quirke, P., Seymour, M. T., Richman, S. D., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0332 · Cited by 772
Cannistra, S. A., Matulonis, U. A., Penson, R. T., Hambleton, J., Dupont, J., Mackey, H., Douglas, J., Burger, R. A., Armstrong, D., Wenham, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0782 · Cited by 759
De Roock, W., Jonker, D. J., Di Nicolantonio, F., Sartore-Bianchi, A., Tu, D., Siena, S., Lamba, S., Arena, S., Frattini, M., Piessevaux, H., et al. (2010) · JAMA · doi:10.1001/jama.2010.1535 · Cited by 748
Poor Survival Associated with the BRAF V600E Mutation in Microsatellite-Stable Colon Cancers
Samowitz, W. S., Sweeney, C., Herrick, J., Albertsen, H., Levin, T. R., Murtaugh, M. A., Wolff, R. K., & Slattery, M. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0404 · Cited by 737
Factors influencing the natural history of colorectal liver metastases
Stangl, R., Altendorf-Hofmann, A., Charnley, R. M., & Scheele, J. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92529-1 · Cited by 722
Amstutz, U., Henricks, L. M., Offer, S. M., Barbarino, J., Schellens, J. H. M., Swen, J. J., Klein, T. E., McLeod, H. L., Caudle, K. E., Diasio, R. B., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.911 · Cited by 694
Hurwitz, H. I., Fehrenbacher, L., Hainsworth, J. D., Heim, W., Berlin, J., Holmgren, E., Hambleton, J., Novotny, W. F., & Kabbinavar, F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.017 · Cited by 688
Kabbinavar, F. F., Hambleton, J., Mass, R. D., Hurwitz, H. I., Bergsland, E., & Sarkar, S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.232 · Cited by 686
Laurent-Puig, P., Cayre, A., Manceau, G., Buc, E., Bachet, J.-B., Lecomte, T., Rougier, P., Lievre, A., Landi, B., Boige, V., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6796 · Cited by 673
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
Hofmann, L., Forschner, A., Loquai, C., Goldinger, S. M., Zimmer, L., Ugurel, S., Schmidgen, M. I., Gutzmer, R., Utikal, J. S., Göppner, D., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.025 · Cited by 649
Cunningham, D., Lang, I., Marcuello, E., Lorusso, V., Ocvirk, J., Shin, D. B., Jonker, D., Osborne, S., Andre, N., Waterkamp, D., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70154-2 · Cited by 643
Schwartzberg, L. S., Rivera, F., Karthaus, M., Fasola, G., Canon, J.-L., Hecht, J. R., Yu, H., Oliner, K. S., & Go, W. Y. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.2473 · Cited by 635
Self-citationKoopman, M., Antonini, N. F., Douma, J., Wals, J., Honkoop, A. H., Erdkamp, F. L., de Jong, R. S., Rodenburg, C. J., Vreugdenhil, G., Loosveld, O. J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61086-1 · Cited by 630
Hochster, H. S., Hart, L. L., Ramanathan, R. K., Childs, B. H., Hainsworth, J. D., Cohn, A. L., Wong, L., Fehrenbacher, L., Abubakr, Y., Saif, M. W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4138 · Cited by 613
Allegra, C. J., Yothers, G., O'Connell, M. J., Sharif, S., Petrelli, N. J., Colangelo, L. H., Atkins, J. N., Seay, T. E., Fehrenbacher, L., Goldberg, R. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.0855 · Cited by 593
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer
Corcoran, R. B., André, T., Atreya, C. E., Schellens, J. H. M., Yoshino, T., Bendell, J. C., Hollebecque, A., McRee, A. J., Siena, S., Middleton, G., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1226 · Cited by 592
Towards a pan-European consensus on the treatment of patients with colorectal liver metastases
Van Cutsem, E., Nordlinger, B., Adam, R., Köhne, C.-H., Pozzo, C., Poston, G., Ychou, M., & Rougier, P. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.04.012 · Cited by 587
Bokemeyer, C., Cutsem, E. V., Rougier, P., Ciardiello, F., Heeger, S., Schlichting, M., Celik, I., & Köhne, C.-H. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.02.057 · Cited by 585
Mitry, E., Fields, A. L. A., Bleiberg, H., Labianca, R., Portier, G., Tu, D., Nitti, D., Torri, V., Elias, D., O'Callaghan, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.3781 · Cited by 583
Meric-Bernstam, F., Hurwitz, H., Raghav, K. P. S., McWilliams, R. R., Fakih, M., VanderWalde, A., Swanton, C., Kurzrock, R., Burris, H., Sweeney, C., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30904-5 · Cited by 573
Loupakis, F., Ruzzo, A., Cremolini, C., Vincenzi, B., Salvatore, L., Santini, D., Masi, G., Stasi, I., Canestrari, E., Rulli, E., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605177 · Cited by 564
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
Zimmer, L., Goldinger, S. M., Hofmann, L., Loquai, C., Ugurel, S., Thomas, I., Schmidgen, M. I., Gutzmer, R., Utikal, J. S., Göppner, D., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.024 · Cited by 562
Seymour, M. T., Maughan, T. S., Ledermann, J. A., Topham, C., James, R., Gwyther, S. J., Smith, D. B., Shepherd, S., Maraveyas, A., Ferry, D. R., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61087-3 · Cited by 561
Sorich, M. J., Wiese, M. D., Rowland, A., Kichenadasse, G., McKinnon, R. A., & Karapetis, C. S. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu378 · Cited by 540
Scappaticci, F. A., Fehrenbacher, L., Cartwright, T., Hainsworth, J. D., Heim, W., Berlin, J., Kabbinavar, F., Novotny, W., Sarkar, S., & Hurwitz, H. (2005) · Journal of Surgical Oncology · doi:10.1002/jso.20301 · Cited by 537
Alberts, S. R., Horvath, W. L., Sternfeld, W. C., Goldberg, R. M., Mahoney, M. R., Dakhil, S. R., Levitt, R., Rowland, K., Nair, S., Sargent, D. J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.740 · Cited by 537
de Gramont, A., Van Cutsem, E., Schmoll, H.-J., Tabernero, J., Clarke, S., Moore, M. J., Cunningham, D., Cartwright, T. H., Hecht, J. R., Rivera, F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70509-0 · Cited by 529
Self-citationCassidy, J., Tabernero, J., Twelves, C., Brunet, R., Butts, C., Conroy, T., Debraud, F., Figer, A., Grossmann, J., Sawada, N., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.069 · Cited by 525
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer
Koopman, M., Kortman, G. A. M., Mekenkamp, L., Ligtenberg, M. J. L., Hoogerbrugge, N., Antonini, N. F., Punt, C. J. A., & van Krieken, J. H. J. M. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604867 · Cited by 515
Hainsworth, J. D., Meric-Bernstam, F., Swanton, C., Hurwitz, H., Spigel, D. R., Sweeney, C., Burris, H. A., Bose, R., Yoo, B., Stein, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3780 · Cited by 506
Pietrantonio, F., Petrelli, F., Coinu, A., Di Bartolomeo, M., Borgonovo, K., Maggi, C., Cabiddu, M., Iacovelli, R., Bossi, I., Lonati, V., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.01.054 · Cited by 486
Molecular characterization of cancers with NTRK gene fusions
Gatalica, Z., Xiu, J., Swensen, J., & Vranic, S. (2019) · Modern Pathology · doi:10.1038/s41379-018-0118-3 · Cited by 486
Price, T. J., Peeters, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Suresh, A. S., Thomas, A., Tjulandin, S., Zhang, K., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70118-4 · Cited by 473
Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer
Loupakis, F., Yang, D., Yau, L., Feng, S., Cremolini, C., Zhang, W., Maus, M. K. H., Antoniotti, C., Langer, C., Scherer, S. J., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju427 · Cited by 472
Self-citationBRAF Mutation in Metastatic Colorectal Cancer
Tol, J., Nagtegaal, I. D., & Punt, C. J. A. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0904160 · Cited by 445
Henricks, L. M., Lunenburg, C. A. T. C., de Man, F. M., Meulendijks, D., Frederix, G. W. J., Kienhuis, E., Creemers, G.-J., Baars, A., Dezentjé, V. O., Imholz, A. L. T., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30686-7 · Cited by 444
Microsatellite Instability and BRAF Mutation Testing in Colorectal Cancer Prognostication
Lochhead, P., Kuchiba, A., Imamura, Y., Liao, X., Yamauchi, M., Nishihara, R., Qian, Z. R., Morikawa, T., Shen, J., Meyerhardt, J. A., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt173 · Cited by 442
Self-citationTreatment-Related Mortality With Bevacizumab in Cancer Patients: A Meta-analysis
Ranpura, V., Hapani, S., & Wu, S. (2011) · JAMA · doi:10.1001/jama.2011.51 · Cited by 428
Cremolini, C., Rossini, D., Dell’Aquila, E., Lonardi, S., Conca, E., Del Re, M., Busico, A., Pietrantonio, F., Danesi, R., Aprile, G., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5080 · Cited by 424
Gruenberger, B., Tamandl, D., Schueller, J., Scheithauer, W., Zielinski, C., Herbst, F., & Gruenberger, T. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.7679 · Cited by 423
Cutsem, E. V., Hoff, P. M., Harper, P., Bukowski, R. M., Cunningham, D., Dufour, P., Graeven, U., Lokich, J., Madajewicz, S., Maroun, J. A., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601676 · Cited by 401
Souglakos, J., Androulakis, N., Syrigos, K., Polyzos, A., Ziras, N., Athanasiadis, A., Kakolyris, S., Tsousis, S., Kouroussis, C., Vamvakas, L., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603011 · Cited by 400
Chibaudel, B., Maindrault-Goebel, F., Lledo, G., Mineur, L., André, T., Bennamoun, M., Mabro, M., Artru, P., Carola, E., Flesch, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4344 · Cited by 395
Kopetz, S., Guthrie, K. A., Morris, V. K., Lenz, H.-J., Magliocco, A. M., Maru, D., Yan, Y., Lanman, R., Manyam, G., Hong, D. S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01994 · Cited by 389
Seymour, M. T., Brown, S. R., Middleton, G., Maughan, T., Richman, S., Gwyther, S., Lowe, C., Seligmann, J. F., Wadsley, J., Maisey, N., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70163-3 · Cited by 388
Prevention of Oxaliplatin-Related Neurotoxicity by Calcium and Magnesium Infusions
Gamelin, L., Boisdron‐Celle, M., Delva, R., Guerin‐Meyer, V., Ifrah, N., Morel, A., & Gamelin, E. C. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0666 · Cited by 385
Meulendijks, D., Henricks, L. M., Sonke, G. S., Deenen, M. J., Froehlich, T. K., Amstutz, U., Largiadèr, C. R., Jennings, B. A., Marinaki, A. M., Sanderson, J. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00286-7 · Cited by 381
Anti–PD-1–Related Pneumonitis during Cancer Immunotherapy
Nishino, M., Sholl, L. M., Hatabu, H., Ramaiya, N. H., & Hodi, F. S. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1505197 · Cited by 373
Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis
Deenen, M. J., Meulendijks, D., Cats, A., Sechterberger, M. K., Severens, J. L., Boot, H., Smits, P. H., Rosing, H., Mandigers, C. M. P. W., Soesan, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.1325 · Cited by 360
Sul, J., Blumenthal, G. M., Jiang, X., He, K., Keegan, P., & Pazdur, R. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0498 · Cited by 359
Gruenberger, T., Bridgewater, J., Chau, I., García Alfonso, P., Rivoire, M., Mudan, S., Lasserre, S., Hermann, F., Waterkamp, D., & Adam, R. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu580 · Cited by 356
Tejpar, S., Celik, I., Schlichting, M., Sartorius, U., Bokemeyer, C., & Van Cutsem, E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.2592 · Cited by 353
Venook, A. P., Niedzwiecki, D., Innocenti, F., Fruth, B., Greene, C., O'Neil, B. H., Shaw, J. E., Atkins, J. N., Horvath, L. E., Polite, B. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3504 · Cited by 336
Self-citationCremolini, C., Antoniotti, C., Rossini, D., Lonardi, S., Loupakis, F., Pietrantonio, F., Bordonaro, R., Latiano, T. P., Tamburini, E., Santini, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30862-9 · Cited by 334
Brulé, S. Y., Jonker, D. J., Karapetis, C. S., O’Callaghan, C. J., Moore, M. J., Wong, R., Tebbutt, N. C., Underhill, C., Yip, D., Zalcberg, J. R., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.03.015 · Cited by 332
Yoshino, T., Mizunuma, N., Yamazaki, K., Nishina, T., Komatsu, Y., Baba, H., Tsuji, A., Yamaguchi, K., Muro, K., Sugimoto, N., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70345-5 · Cited by 326
Rowland, A., Dias, M. M., Wiese, M. D., Kichenadasse, G., McKinnon, R. A., Karapetis, C. S., & Sorich, M. J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.173 · Cited by 319
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
Valtorta, E., Martino, C., Sartore-Bianchi, A., Penaullt-Llorca, F., Viale, G., Risio, M., Rugge, M., Grigioni, W., Bencardino, K., Lonardi, S., et al. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.98 · Cited by 313
Tumor mutational burden quantification from targeted gene panels: major advancements and challenges
Fancello, L., Gandini, S., Pelicci, P. G., & Mazzarella, L. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0647-4 · Cited by 310
Knijn, N., Mekenkamp, L. J. M., Klomp, M., Vink-Börger, M. E., Tol, J., Teerenstra, S., Meijer, J. W. R., Tebar, M., Riemersma, S., van Krieken, J. H. J. M., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.26 · Cited by 291
Yahagi, M., Okabayashi, K., Hasegawa, H., Tsuruta, M., & Kitagawa, Y. (2016) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-015-3026-6 · Cited by 286
Bekaii-Saab, T. S., Ou, F.-S., Ahn, D. H., Boland, P. M., Ciombor, K. K., Heying, E. N., Dockter, T. J., Jacobs, N. L., Pasche, B. C., Cleary, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30272-4 · Cited by 283
Self-citationPorschen, R., Arkenau, H.-T., Kubicka, S., Greil, R., Seufferlein, T., Freier, W., Kretzschmar, A., Graeven, U., Grothey, A., Hinke, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2684 · Cited by 280
Yamazaki, K., Nagase, M., Tamagawa, H., Ueda, S., Tamura, T., Murata, K., Eguchi Nakajima, T., Baba, E., Tsuda, M., Moriwaki, T., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw206 · Cited by 268
André, T., Louvet, C., Maindrault-Goebel, F., Couteau, C., Mabro, M., Lotz, J. P., Gilles-Amar, V, Krulik, M., Carola, E., Izrael, V, et al. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00150-1 · Cited by 267
Allegra, C. J., Rumble, R. B., Hamilton, S. R., Mangu, P. B., Roach, N., Hantel, A., & Schilsky, R. L. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.9674 · Cited by 264
Cheng, L., Eng, C., Nieman, L. Z., Kapadia, A. S., & Du, X. L. (2011) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3181fe41ed · Cited by 263
Elias, D., Liberale, G., Vernerey, D., Pocard, M., Ducreux, M., Boige, V., Malka, D., Pignon, J.-P., & Lasser, P. (2005) · Annals of Surgical Oncology · doi:10.1245/aso.2005.01.010 · Cited by 261
Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines
Haller, D. G., Cassidy, J., Clarke, S. J., Cunningham, D., Van Cutsem, E., Hoff, P. M., Rothenberg, M. L., Saltz, L. B., Schmoll, H.-J., Allegra, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2090 · Cited by 252
Self-citationTabernero, J., Van Cutsem, E., Lakomý, R., Prausová, J., Ruff, P., van Hazel, G. A., Moiseyenko, V. M., Ferry, D. R., McKendrick, J. J., Soussan-Lazard, K., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.09.013 · Cited by 242
The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer
Goldberg, R. M., Rothenberg, M. L., Van Cutsem, E., Benson, A. B., Blanke, C. D., Diasio, R. B., Grothey, A., Lenz, H.-J., Meropol, N. J., Ramanathan, R. K., et al. (2007) · The Oncologist · doi:10.1634/theoncologist.12-1-38 · Cited by 239
Self-citationHurwitz, H. I., Tebbutt, N. C., Kabbinavar, F., Giantonio, B. J., Guan, Z.-Z., Mitchell, L., Waterkamp, D., & Tabernero, J. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0107 · Cited by 236
Morel, A., Boisdron-Celle, M., Fey, L., Soulie, P., Craipeau, M. C., Traore, S., & Gamelin, E. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0327 · Cited by 236
Cremolini, C., Antoniotti, C., Stein, A., Bendell, J., Gruenberger, T., Rossini, D., Masi, G., Ongaro, E., Hurwitz, H., Falcone, A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01225 · Cited by 235
Peeters, M., Douillard, J.-Y., Van Cutsem, E., Siena, S., Zhang, K., Williams, R., & Wiezorek, J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.1492 · Cited by 232
Pfeiffer, P., Yilmaz, M., Möller, S., Zitnjak, D., Krogh, M., Petersen, L. N., Poulsen, L. Ø., Winther, S. B., Thomsen, K. G., & Qvortrup, C. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30827-7 · Cited by 232
Rowland, A., Dias, M. M., Wiese, M. D., Kichenadasse, G., McKinnon, R. A., Karapetis, C. S., & Sorich, M. J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.325 · Cited by 229
Hurwitz, H. I., Saltz, L. B., Van Cutsem, E., Cassidy, J., Wiedemann, J., Sirzén, F., Lyman, G. H., & Rohr, U.-P. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.3220 · Cited by 226
Self-citationVan Cutsem, E., Huijberts, S., Grothey, A., Yaeger, R., Cuyle, P.-J., Elez, E., Fakih, M., Montagut, C., Peeters, M., Yoshino, T., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02459 · Cited by 224
XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
Cassidy, J., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Rittweger, K., Gilberg, F., & Saltz, L. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.201 · Cited by 224
Self-citationSafaee Ardekani, G., Jafarnejad, S. M., Tan, L., Saeedi, A., & Li, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047054 · Cited by 224
Better survival in right-sided versus left-sided stage I - III colon cancer patients
Warschkow, R., Sulz, M. C., Marti, L., Tarantino, I., Schmied, B. M., Cerny, T., & Güller, U. (2016) · BMC Cancer · doi:10.1186/s12885-016-2412-0 · Cited by 220
Peeters, M., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., Punt, C. J. A., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt523 · Cited by 219
Price, T. J., Hardingham, J. E., Lee, C. K., Weickhardt, A., Townsend, A. R., Wrin, J. W., Chua, A., Shivasami, A., Cummins, M. M., Murone, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.5520 · Cited by 209
Grothey, A., Nikcevich, D. A., Sloan, J. A., Kugler, J. W., Silberstein, P. T., Dentchev, T., Wender, D. B., Novotny, P. J., Chitaley, U., Alberts, S. R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.5911 · Cited by 198
Sargent, D. J., Köhne, C. H., Sanoff, H. K., Bot, B. M., Seymour, M. T., de Gramont, A., Porschen, R., Saltz, L. B., Rougier, P., Tournigand, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.2879 · Cited by 196
Self-citationMutations of KRAS and BRAF in Primary and Matched Metastatic Sites of Colorectal Cancer
Artale, S., Sartore-Bianchi, A., Veronese, S. M., Gambi, V., Sarnataro, C. S., Gambacorta, M., Lauricella, C., & Siena, S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.7286 · Cited by 192
Lee, A. M., Shi, Q., Pavey, E., Alberts, S. R., Sargent, D. J., Sinicrope, F. A., Berenberg, J. L., Goldberg, R. M., & Diasio, R. B. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju298 · Cited by 189
Masi, G., Vasile, E., Loupakis, F., Cupini, S., Fornaro, L., Baldi, G., Salvatore, L., Cremolini, C., Stasi, I., Brunetti, I., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq456 · Cited by 188
Welch, S., Spithoff, K., Rumble, R. B., & Maroun, J. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp533 · Cited by 187
Peeters, M., Oliner, K. S., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0526 · Cited by 181
Yoon, H. H., Tougeron, D., Shi, Q., Alberts, S. R., Mahoney, M. R., Nelson, G. D., Nair, S., Thibodeau, S. N., Goldberg, R. M., Sargent, D. J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3140 · Cited by 179
Kuboki, Y., Nishina, T., Shinozaki, E., Yamazaki, K., Shitara, K., Okamoto, W., Kajiwara, T., Matsumoto, T., Tsushima, T., Mochizuki, N., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30425-4 · Cited by 176
Muratore, A., Zorzi, D., Bouzari, H., Amisano, M., Massucco, P., Sperti, E., & Capussotti, L. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9146-1 · Cited by 173
Reddy, S. K., Morse, M. A., Hurwitz, H. I., Bendell, J. C., Gan, T. J., Hill, S. E., & Clary, B. M. (2008) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2007.06.290 · Cited by 172
Masi, G., Salvatore, L., Boni, L., Loupakis, F., Cremolini, C., Fornaro, L., Schirripa, M., Cupini, S., Barbara, C., Safina, V., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv012 · Cited by 172
HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer
Sartore-Bianchi, A., Amatu, A., Porcu, L., Ghezzi, S., Lonardi, S., Leone, F., Bergamo, F., Fenocchio, E., Martinelli, E., Borelli, B., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0785 · Cited by 171
Ducreux, M. P., Malka, D., Mendiboure, J., Etienne, P.-L., Texereau, P., Auby, D., Rougier, P. R., Gasmi, M., Castaing, M., Abbas, M., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70199-1 · Cited by 170
Ducreux, M., Bennouna, J., Hebbar, M., Ychou, M., Lledo, G., Conroy, T., Adenis, A., Faroux, R., Rebischung, C., Bergougnoux, L., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.25369 · Cited by 166
O'Dwyer, P. J., & Catalano, R. B. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3031 · Cited by 166
Étienne-Grimaldi, M.-C., Formento, J., Francoual, M., François, É., Formento, P., Renée, N., Laurent‐Puig, P., Chazal, M., Benchimol, D., Delpéro, J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4906 · Cited by 166
Clancy, C., Burke, J. P., Kalady, M. F., & Coffey, J. C. (2013) · Colorectal Disease · doi:10.1111/codi.12427 · Cited by 165
Ikenoue, T., Hikiba, Y., Kanai, F., Tanaka, Y., Imamura, J., Imamura, T., Ohta, M., Ijichi, H., Tateishi, K., Kawakami, T., et al. (2003) · PubMed · Cited by 164
Cocco, E., Benhamida, J., Middha, S., Zehir, A., Mullaney, K., Shia, J., Yaeger, R., Zhang, L., Wong, D., Villafania, L., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3126 · Cited by 163
Self-citationChen, D., Huang, J.-F., Liu, K., Zhang, L.-Q., Yang, Z., Chuai, Z.-R., Wang, Y.-X., Shi, D.-C., Huang, Q., & Fu, W.-L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090607 · Cited by 161
Miles, D., Harbeck, N., Escudier, B., Hurwitz, H., Saltz, L., Van Cutsem, E., Cassidy, J., Mueller, B., & Sirzén, F. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.2794 · Cited by 158
Self-citationLiu, X., Cheng, D., Kuang, Q., Liu, G., & Xu, W. (2013) · The Pharmacogenomics Journal · doi:10.1038/tpj.2013.10 · Cited by 157
Martin, V, Landi, L., Molinari, F., Fountzilas, G., Geva, R., Riva, A., Saletti, P., De Dosso, S., Spitale, A., Tejpar, S., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.4 · Cited by 156
Molecular Biomarkers for the Evaluation of Colorectal Cancer
Sepulveda, A. R., Hamilton, S. R., Allegra, C. J., Grody, W. W., Cushman‐Vokoun, A. M., Funkhouser, W. K., Kopetz, S., Lieu, C. H., Lindor, N. M., Minsky, B. D., et al. (2017) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.11.001 · Cited by 155
Innocenti, F., Schilsky, R. L., Ramírez, J., Janisch, L. A., Undevia, S. D., House, L. K., Das, S., Wu, K., Turcich, M., Marsh, R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.2307 · Cited by 152
Rivera, F., Karthaus, M., Hecht, J. R., Sevilla, I., Forget, F., Fasola, G., Canon, J.-L. R., Guan, X., Demonty, G., & Schwartzberg, L. S. (2017) · International Journal of Colorectal Disease · doi:10.1007/s00384-017-2800-1 · Cited by 152
Self-citationAnti–PD-1 Inhibitor–Related Pneumonitis in Non–Small Cell Lung Cancer
Nishino, M., Chambers, E. S., Chong, C. R., Ramaiya, N. H., Gray, S. W., Marcoux, J. P., Hatabu, H., Janne, P. A., Hodi, F. S., & Awad, M. M. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0267 · Cited by 149
Petrelli, F., Cabiddu, M., Borgonovo, K., & Barni, S. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr592 · Cited by 147
Terrazzino, S., Cargnin, S., Re, M. D., Danesi, R., Canonico, P. L., & Genazzani, A. A. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.116 · Cited by 146
Van Cutsem, E., Martinelli, E., Cascinu, S., Sobrero, A., Banzi, M., Seitz, J.-F., Barone, C., Ychou, M., Peeters, M., Brenner, B., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0072 · Cited by 142
Burtness, B. A., Anadkat, M. J., Basti, S., Hughes, M., Lacouture, M. E., McClure, J. S., Myskowski, P. L., Jennifer, P., Perlis, C., Saltz, L. B., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0074 · Cited by 141
Self-citationMacedo, L. T., Lima, A. B. C., & Sasse, A. D. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-89 · Cited by 140
Meyerhardt, J. A., Li, L., Sanoff, H. K., Carpenter, W. R., & Schrag, D. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.9650 · Cited by 139
Self-citationLunenburg, C. A. T. C., Henricks, L. M., Guchelaar, H., Swen, J. J., Deenen, M. J., Schellens, J. H. M., & Gelderblom, H. A. J. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.008 · Cited by 139
Adenis, A., de la Fouchardière, C., Paule, B., Burtin, P. C., Tougeron, D., Wallet, J., Dourthe, L.-M., Etienne, P.-L., Mineur, L., Clisant, S., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2440-9 · Cited by 137
Cutsem, E. V., Tejpar, S., Vanbeckevoort, D., Peeters, M., Humblet, Y., Gelderblom, H. A. J., Vermorken, J. B., Viret, F., Glimelius, B. L. G., Gallerani, E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.9243 · Cited by 134
Petrelli, F., Borgonovo, K., & Barni, S. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0257-x · Cited by 132
Sobrero, A. F., Ackland, S. P., Clarke, S. J., Pérez-Carrión, R., Chiarra, S., Gapski, J., Mainwaring, P. N., Langer, B., & Young, S. (2009) · Oncology · doi:10.1159/000229787 · Cited by 131
Botrel, T. E. A., Clark, L. G. D. O., Paladini, L. M., & Clark, O. A. C. (2016) · BMC Cancer · doi:10.1186/s12885-016-2734-y · Cited by 130
Arnold, D., Fuchs, C. S., Tabernero, J. M., Ohtsu, A., Zhu, A. X., Garon, E. B., Mackey, J. R., Paz-Ares, L. G., Baron, A. D., Okusaka, T., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx514 · Cited by 130
Research works printed but not linked: 374
- 2020, Drug Administration Package Insert STIVARGA regorafenib tablets for oral use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17
- Yoo, 2006, Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab, Clin Colorectal Cancer, 6, 202, 10.3816/CCC.2006.n.036 · doi:10.3816/ccc.2006.n.036
- LONSURF, 2019, Drug Administration Package Insert trifluridine tipiracil tablets for oral use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17
- Panitumumab, 2017, Administration Package Insert Vectibix Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food Drug, 17, 207
- Resch, 2011, Infusion reactions to the chimeric EGFR inhibitor cetuximab--change to the fully human anti-EGFR monoclonal antibody panitumumab is safe, Ann Oncol, 22, 486, 10.1093/annonc/mdq744 · doi:10.1093/annonc/mdq744
- Wang, 2010, KRAS mutation testing in human cancers: the pathologist’s role in the era of personalized medicine, Adv Anat Pathol, 17, 23, 10.1097/PAP.0b013e3181c6962f · DOI
- Guo, 2016, XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis, Cancer Invest, 34, 94, 10.3109/07357907.2015.1104689 · DOI
- Deenen, 2016, Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis, J Clin Oncol, 34, 227, 10.1200/JCO.2015.63.1325 · DOI · Paper page
- Seymour, 2012, Conceptual approaches to metastatic disease, Ann Oncol, 23, x77, 10.1093/annonc/mds361 · doi:10.1093/annonc/mds361
- Buchler, 2014, Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis, BMC Cancer, 14, 323, 10.1186/1471-2407-14-323 · doi:10.1186/1471-2407-14-323
- Seymour, 2007, Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial, Lancet, 370, 143, 10.1016/S0140-6736(07)61087-3 · DOI · Paper page
- 2019, Drug Administration Package Insert ZIRABEVTM bevacizumab bvzr injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 000
- Nordlinger, 2013, Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial, Lancet Oncol, 14, 1208, 10.1016/S1470-2045(13)70447-9 · DOI · Paper page
- Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, 350, 2335, 10.1056/NEJMoa032691 · DOI · Paper page
- Dai, 2013, Safety of bevacizumab in treating metastatic colorectal cancer: a systematic review and meta-analysis of all randomized clinical trials, Clin Drug Investig, 33, 779, 10.1007/s40261-013-0125-6 · DOI
- Fong, 1997, Liver resection for colorectal metastases, J Clin Oncol, 15, 938, 10.1200/JCO.1997.15.3.938 · DOI · Paper page
- Foster, 1984, Treatment of metastatic disease of the liver: a skeptic’s view, Semin Liver Dis, 4, 170, 10.1055/s-2008-1040656 · doi:10.1055/s-2008-1040656
- Chibaudel, 2009, Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study, J Clin Oncol, 27, 5727, 10.1200/JCO.2009.23.4344 · DOI · Paper page
- Kurniali, 2010, Role of calcium/ magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients, Oncology (Williston Park), 24, 289
- Hochster, 2007, Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity, J Clin Oncol, 25, 4028, 10.1200/JCO.2007.13.5251 · doi:10.1200/jco.2007.13.5251
- Schmoll, 2017, “CHARTA”: FOLFOX/bevacizumab vs FOLFOXIRI/bevacizumab in advanced colorectal cancer—Final results, prognostic and potentially predictive factors from the randomized Phase II trial of the AIO, J Clin Oncol, 35, 3533, 10.1200/JCO.2017.35.15_suppl.3533 · doi:10.1200/jco.2017.35.15_suppl.3533
- Muratore, 2007, Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy?, Ann Surg Oncol, 14, 766, 10.1245/s10434-006-9146-1 · DOI · Paper page
- OPDIVO, 2020, Drug Administration Package Insert nivolumab injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 071
- Hoff, 2004, Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma, J Clin Oncol, 22, 2078, 10.1200/JCO.2004.05.072 · doi:10.1200/jco.2004.05.072
- Berlin, 2020, Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer, J Clin Oncol, 38, 824, 10.1200/JCO.2020.38.4_suppl.824 · doi:10.1200/jco.2020.38.4_suppl.824
- OPDIVO, 2020, Drug Administration Package Insert nivolumab injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 071
- Van Cutsem, 2004, Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials, Br J Cancer, 90, 1190, 10.1038/sj.bjc.6601676 · DOI · Paper page
- Knijn, 2011, The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients, Eur J Cancer, 47, 369, 10.1016/j.ejca.2010.10.006 · doi:10.1016/j.ejca.2010.10.006
- 2020, Drug Administration Package Insert KEYTRUDA pembrolizumab injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 088
- Miles, 2011, Reply to P. Potemski, J Clin Oncol, 29, e386, 10.1200/JCO.2010.34.1479 · doi:10.1200/jco.2010.34.1479
- Besora, 2018, Rechallenge with oxaliplatin and peripheral neuropathy in colorectal cancer patients, J Cancer Res Clin Oncol, 144, 1793, 10.1007/s00432-018-2691-8 · doi:10.1007/s00432-018-2691-8
- Allegra, 2011, Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08, J Clin Oncol, 29, 11, 10.1200/JCO.2010.30.0855 · DOI · Paper page
- Graham, 2018, A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US, J Med Econ, 21, 1075, 10.1080/13696998.2018.1510409 · DOI
- Le, 2020, Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164, J Clin Oncol, 38, 11, 10.1200/JCO.19.02107 · DOI · Paper page
- Cassidy, 2008, Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer, J Clin Oncol, 26, 2006, 10.1200/JCO.2007.14.9898 · DOI · Paper page
- Tsai, 2007, Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis, Ann Surg Oncol, 14, 786, 10.1245/s10434-006-9215-5 · doi:10.1245/s10434-006-9215-5
- Zimmer, 2016, Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy, Eur J Cancer, 60, 210, 10.1016/j.ejca.2016.02.024 · DOI · Paper page
- Sorich, 2015, Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials, Ann Oncol, 26, 13, 10.1093/annonc/mdu378 · DOI · Paper page
- CYRAMZA, 2020, Drug Administration Package Insert ramucirumab injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 037
- Resch, 2011, Infusion reactions to the chimeric EGFR inhibitor cetuximab--change to the fully human anti-EGFR monoclonal antibody panitumumab is safe, Ann Oncol, 22, 486, 10.1093/annonc/mdq744 · doi:10.1093/annonc/mdq744
- Van Cutsem, 2011, Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status, J Clin Oncol, 29, 2011, 10.1200/JCO.2010.33.5091 · DOI · Paper page
- Kopetz, 2020, Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406) [abstract]., J Clin Oncol, 35, JCO2001994
- 2019, Drug Administration Package Insert TRAZIMERATM trastuzumab qyyp for injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 000
- Kurniali, 2010, Role of calcium/ magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients, Oncology (Williston Park), 24, 289
- Lee, 2007, Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival, Int J Colorectal Dis, 22, 699, 10.1007/s00384-006-0218-2 · DOI
- Maughan, 2011, Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial, Lancet, 377, 2103, 10.1016/S0140-6736(11)60613-2 · DOI · Paper page
- Loprinzi, 2014, Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance), J Clin Oncol, 32, 997, 10.1200/JCO.2013.52.0536 · doi:10.1200/jco.2013.52.0536
- Novmeber, 2019, Drug Administration Package Insert KANJINTI trastuzumab anns for injection for intravenous use Accessed Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 1
- Koopman, 2009, Deficient mismatch repair system in patients with sporadic advanced colorectal cancer, Br J Cancer, 100, 266, 10.1038/sj.bjc.6604867 · DOI · Paper page
- Miles, 2011, Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials, J Clin Oncol, 29, 83, 10.1200/JCO.2010.30.2794 · DOI · Paper page
- Innocenti, 2014, Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer, J Clin Oncol, 32, 2328, 10.1200/JCO.2014.55.2307 · DOI
- Novmeber, 2019, Drug Administration Package Insert KANJINTI trastuzumab anns for injection for intravenous use Accessed Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 1
- Berry, 2015, Continuous versus intermittent chemotherapy strategies in metastatic colorectal cancer: a systematic review and meta-analysis, Ann Oncol, 26, 477, 10.1093/annonc/mdu272 · DOI
- Kidwell, 2012, Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01, Cancer, 118, 5614, 10.1002/cncr.27593 · DOI
- Saltz, 2004, Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor, J Clin Oncol, 22, 1201, 10.1200/JCO.2004.10.182 · DOI · Paper page
- Lenz, 2019, Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): clinical update, J Clin Oncol, 37, 3521, 10.1200/JCO.2019.37.15_suppl.3521 · DOI
- Gupta, 2020, Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with ERBB2 amplification or overexpression: Results from the TAPUR Study [abstract], J Clin Oncol, 38, 132, 10.1200/JCO.2020.38.4_suppl.132 · DOI · Paper page
- 2019, Drug Administration Package Insert ONTRUZANT trastuzumab dttb for injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 000
- Gamelin, 2008, Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy, J Clin Oncol, 26, 1188, 10.1200/JCO.2007.15.3767 · doi:10.1200/jco.2007.15.3767
- Erbitux, 2020, Drug Administration Package Insert cetuximab injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 275
- Costa, 2017, REOX: evaluation of the efficacy of retreatment with an oxaliplatin-containing regimen in metastatic colorectal cancer: a retrospective single-center study, Clin Colorectal Cancer, 16, 316, 10.1016/j.clcc.2017.03.002 · DOI
- 2019, Drug Administration Package Insert ZIRABEVTM bevacizumab bvzr injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 000
- Zhang, 2012, Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: meta-analysis of randomized controlled trials, Oncol Lett, 3, 831
- Nishino, 2016, Anti-PD-1 inhibitor-related pneumonitis in non-small cell lung cancer, Cancer Immunol Res, 4, 289, 10.1158/2326-6066.CIR-15-0267 · DOI
- Goldstein, 2015, Considering efficacy and cost, where does ramucirumab fit in the management of metastatic colorectal cancer?, Oncologist, 20, 981, 10.1634/theoncologist.2015-0028 · DOI
- Di Nicolantonio, 2008, Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer, J Clin Oncol, 26, 5705, 10.1200/JCO.2008.18.0786 · DOI · Paper page
- Miles, 2011, Reply to P. Potemski, J Clin Oncol, 29, e386, 10.1200/JCO.2010.34.1479 · doi:10.1200/jco.2010.34.1479
- Tsai, 2007, Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis, Ann Surg Oncol, 14, 786, 10.1245/s10434-006-9215-5 · doi:10.1245/s10434-006-9215-5
- 2019, Drug Administration Package Insert HERZUMA trastuzumab pkrb for injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 001
- Deenen, 2016, Reply to T. Magnes et al, J Clin Oncol, 34, 2434, 10.1200/JCO.2016.67.4374 · doi:10.1200/jco.2016.67.4374
- Hurwitz, 2005, Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer, J Clin Oncol, 23, 3502, 10.1200/JCO.2005.10.017 · DOI · Paper page
- Hurwitz, 2013, Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials, Oncologist, 18, 1004, 10.1634/theoncologist.2013-0107 · DOI · Paper page
- Yoo, 2006, Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab, Clin Colorectal Cancer, 6, 202, 10.3816/CCC.2006.n.036 · doi:10.3816/ccc.2006.n.036
- 2019, Drug Administration Package Insert TRAZIMERATM trastuzumab qyyp for injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 000
- Iwamoto, 2015, FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study, Ann Oncol, 26, 1427, 10.1093/annonc/mdv197 · DOI
- Cassidy, 2004, XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer, J Clin Oncol, 22, 2084, 10.1200/JCO.2004.11.069 · DOI · Paper page
- Petrelli, 2013, The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials, Target Oncol, 8, 173, 10.1007/s11523-013-0257-x · DOI
- Bailey, 2014, Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010, JAMA Surg, 32, 1
- 2019, Drug Administration Package Insert MVASI bevacizumab awwb injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17
- Meulendijks, 2015, Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data, Lancet Oncol, 16, 1639, 10.1016/S1470-2045(15)00286-7 · DOI · Paper page
- Tabernero, 2014, Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial, Eur J Cancer, 50, 320, 10.1016/j.ejca.2013.09.013 · DOI · Paper page
- Moretto, 2016, Location of primary tumor and benefit from anti-epidermal growth factor receptor monoclonal antibodies in patients with RAS and BRAF wild-type metastatic colorectal cancer, Oncologist, 21, 988, 10.1634/theoncologist.2016-0084 · DOI
- Bennouna, 2013, Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial, Lancet Oncol, 14, 29, 10.1016/S1470-2045(12)70477-1 · DOI · Paper page
- André, 2020, Pembrolizumab in microsatellite-instability-high advanced colorectal cancer, N Engl J Med, 383, 2207, 10.1056/NEJMoa2017699 · DOI · Paper page
- Adenis, 2016, Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program, BMC Cancer, 16, 412, 10.1186/s12885-016-2440-9 · DOI
- Hayashi, 2010, Clinicopathological analysis of recurrence patterns and prognostic factors for survival after hepatectomy for colorectal liver metastasis, BMC Surg, 10, 27, 10.1186/1471-2482-10-27 · DOI
- Valtorta, 2015, Assessment of a HER2 scoring system for colorectal cancer: results from a validation study, Mod Pathol, 28, 1481, 10.1038/modpathol.2015.98 · DOI · Paper page
- Stangl, 1994, Factors influencing the natural history of colorectal liver metastases, Lancet, 343, 1405, 10.1016/S0140-6736(94)92529-1 · DOI · Paper page
- Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690 · DOI · Paper page
- Peeters, 2013, Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab, J Clin Oncol, 31, 759, 10.1200/JCO.2012.45.1492 · DOI · Paper page
- Kubicka, 2013, Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings, Ann Oncol, 24, 2342, 10.1093/annonc/mdt231 · DOI · Paper page
- Erbitux, 2020, Drug Administration Package Insert cetuximab injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 275
- 2019, Drug Administration Package Insert ROZLYTREK entrectinib capsules for oral use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 000
- Cao, 2009, A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer, Int J Colorectal Dis, 24, 677, 10.1007/s00384-009-0655-9 · DOI
- Schmoll, 2006, Update on capecitabine in colorectal cancer, Oncologist, 11, 1003, 10.1634/theoncologist.11-9-1003 · DOI
- 2020, Drug Administration Package Insert ELOXATIN oxaliplatin injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 021759
- Haller, 2008, Potential regional differences for the tolerability profiles of fluoropyrimidines, J Clin Oncol, 26, 2118, 10.1200/JCO.2007.15.2090 · DOI · Paper page
- Ducreux, 2011, Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer, Int J Cancer, 128, 682, 10.1002/ijc.25369 · DOI · Paper page
- Venderbosch, 2014, Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies, Clin Cancer Res, 20, 5322, 10.1158/1078-0432.CCR-14-0332 · DOI · Paper page
- Deenen, 2016, Reply to T. Magnes et al, J Clin Oncol, 34, 2434, 10.1200/JCO.2016.67.4374 · doi:10.1200/jco.2016.67.4374
- Berlin, 2020, Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer, J Clin Oncol, 38, 824, 10.1200/JCO.2020.38.4_suppl.824 · doi:10.1200/jco.2020.38.4_suppl.824
- 2018, Drug Administration Package Insert VITRAKVI larotrectinib capsules for oral use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 000
- Hurwitz, 2014, Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study, Clin Oncol (R Coll Radiol), 26, 323, 10.1016/j.clon.2014.03.001 · DOI
- Fourrier-Réglat, 2014, Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort, Target Oncol, 9, 311, 10.1007/s11523-013-0296-3 · DOI
- Lee, 2007, Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival, Int J Colorectal Dis, 22, 699, 10.1007/s00384-006-0218-2 · DOI
- Marabelle, 2020, Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study, Lancet Oncol, 21, 1353, 10.1016/S1470-2045(20)30445-9 · DOI · Paper page
- Kim, 2016, A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer, Br J Cancer, 115, 1206, 10.1038/bjc.2016.309 · DOI
- Henricks, 2019, A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy, Eur J Cancer, 107, 60, 10.1016/j.ejca.2018.11.010 · DOI
- Reddy, 2008, Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases, J Am Coll Surg, 206, 96, 10.1016/j.jamcollsurg.2007.06.290 · DOI · Paper page
- Clancy, 2013, BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis, Colorectal Dis, 15, e711, 10.1111/codi.12427 · DOI
- Kabbinavar, 2005, Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer, J Clin Oncol, 23, 3706, 10.1200/JCO.2005.00.232 · DOI · Paper page
- CYRAMZA, 2020, Drug Administration Package Insert ramucirumab injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 037
- Yalcin, 2013, Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III ‘Stop and Go’ study results--a Turkish Oncology Group Trial, Oncology, 85, 328, 10.1159/000355914 · DOI
- Petrelli, 2012, Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials, Ann Oncol, 23, 1672, 10.1093/annonc/mdr592 · DOI
- Peeters, 2010, Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer, J Clin Oncol, 28, 4706, 10.1200/JCO.2009.27.6055 · DOI · Paper page
- Snoeren, 2017, Randomized phase III study to assess efficacy and safety of adjuvant CAPOX with or without bevacizumab in patients after resection of colorectal liver metastases: HEPATICA study, Neoplasia, 19, 93, 10.1016/j.neo.2016.08.010 · DOI
- Kopetz, 2019, Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer, N Engl J Med, 381, 1632, 10.1056/NEJMoa1908075 · DOI · Paper page
- Seymour, 2012, Conceptual approaches to metastatic disease, Ann Oncol, 23, x77, 10.1093/annonc/mds361 · doi:10.1093/annonc/mds361
- Venook, 2017, Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial, JAMA, 317, 2392, 10.1001/jama.2017.7105 · DOI · Paper page
- Van Cutsem, 2019, Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E-mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON colorectal cancer study, J Clin Oncol, 37, 1460, 10.1200/JCO.18.02459 · DOI · Paper page
- Grothey, 2014, Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study, Pharmacoepidemiol Drug Saf, 23, 726, 10.1002/pds.3633 · DOI
- AVASTIN, 2020, Administration Package Insert bevacizumab injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food Drug, 17, 336
- de Gramont, 2012, Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial, Lancet Oncol, 13, 1225, 10.1016/S1470-2045(12)70509-0 · DOI · Paper page
- Pawlik, 2005, Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases, Ann Surg, 241, 715, 10.1097/01.sla.0000160703.75808.7d · DOI · Paper page
- Loupakis, 2010, Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials, J Exp Clin Cancer Res, 29, 58, 10.1186/1756-9966-29-58 · DOI
- De Roock, 2008, KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab, Ann Oncol, 19, 508, 10.1093/annonc/mdm496 · DOI · Paper page
- 2020, Drug Administration Package Insert STIVARGA regorafenib tablets for oral use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17
- Wan, 2004, Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF, Cell, 116, 855, 10.1016/S0092-8674(04)00215-6 · DOI · Paper page
- Cunningham, 1998, Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer, Lancet, 352, 1413, 10.1016/S0140-6736(98)02309-5 · DOI · Paper page
- Siena, 2020, A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01 [abstract], J Clin Oncol, 38, 4000, 10.1200/JCO.2020.38.15_suppl.4000 · DOI · Paper page
- O’Neil, 2015, Trying to understand differing results of FIRE-3 and 80405: does the first treatment matter more than others?, J Clin Oncol, 33, 3686, 10.1200/JCO.2015.62.8495 · DOI
- Liu, 2015, Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response, BMC Cancer, 15, 713, 10.1186/s12885-015-1701-3 · DOI
- Cassidy, 2011, XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results, Br J Cancer, 105, 58, 10.1038/bjc.2011.201 · DOI · Paper page
- Petrelli, 2013, FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials, Clin Colorectal Cancer, 12, 145, 10.1016/j.clcc.2013.04.006 · DOI
- Cocco, 2019, Colorectal carcinomas containing hypermethylated MLH1 promoter and wild-type BRAF/KRAS are enriched for targetable kinase fusions, Cancer Res, 79, 1047, 10.1158/0008-5472.CAN-18-3126 · DOI · Paper page
- Cremolini, 2015, FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study, Lancet Oncol, 16, 1306, 10.1016/S1470-2045(15)00122-9 · DOI · Paper page
- Van Cutsem, 2009, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer, N Engl J Med, 360, 1408, 10.1056/NEJMoa0805019 · DOI · Paper page
- Sartore-Bianchi, 2016, Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial, Lancet Oncol, 17, 738, 10.1016/S1470-2045(16)00150-9 · DOI · Paper page
- Rowland, 2016, Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours, Eur J Cancer, 55, 122, 10.1016/j.ejca.2015.11.025 · DOI
- Mattison, 2002, Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics, Pharmacogenomics, 3, 485, 10.1517/14622416.3.4.485 · DOI
- Botrel, 2016, Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis, BMC Cancer, 16, 677, 10.1186/s12885-016-2734-y · DOI
- Kajitani, 2017, Anti-epidermal growth factor receptor antibody readministration in chemorefractory metastatic colorectal cancer, Anticancer Res, 37, 6459
- Giantonio, 2007, Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200, J Clin Oncol, 25, 1539, 10.1200/JCO.2006.09.6305 · DOI · Paper page
- Belum, 2013, Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis, Invest New Drugs, 31, 1078, 10.1007/s10637-013-9977-0 · DOI
- 2020, Drug Administration Package Insert KEYTRUDA pembrolizumab injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 088
- Liu, 2014, Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians, Pharmacogenomics J, 14, 120, 10.1038/tpj.2013.10 · DOI
- Hurwitz, 2012, Registries and randomized trials in assessing the effects of bevacizumab in colorectal cancer: is there a common theme?, J Clin Oncol, 30, 580, 10.1200/JCO.2011.40.7031 · DOI
- Roth, 2010, Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial, J Clin Oncol, 28, 466, 10.1200/JCO.2009.23.3452 · DOI · Paper page
- Cremolini, 2020, Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer, J Clin Oncol, 38, 3314, 10.1200/JCO.20.01225 · DOI · Paper page
- Arnold, 2017, Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials, Ann Oncol, 28, 1713, 10.1093/annonc/mdx175 · DOI · Paper page
- 2019, Drug Administration Package Insert OGIVRI trastuzumab dkst for injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17
- Riesco-Martínez, 2016, Cost-effectiveness analysis of different sequences of the use of epidermal growth factor receptor inhibitors for wild-type KRAS unresectable metastatic colorectal cancer, J Oncol Pract, 12, e710, 10.1200/JOP.2015.008730 · DOI
- Helbling, 2007, Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab, Ann Oncol, 18, 963, 10.1093/annonc/mdm130 · doi:10.1093/annonc/mdm130
- Cheng, 2011, Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005, Am J Clin Oncol, 34, 573, 10.1097/COC.0b013e3181fe41ed · DOI · Paper page
- 2019, Drug Administration Package Insert ROZLYTREK entrectinib capsules for oral use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 000
- Wu, 2015, Does overexpression of HER-2 correlate with clinicopathological characteristics and prognosis in colorectal cancer? Evidence from a meta-analysis, Diagn Pathol, 10, 144, 10.1186/s13000-015-0380-3 · DOI
- Drilon, 2018, Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children, N Engl J Med, 378, 731, 10.1056/NEJMoa1714448 · DOI · Paper page
- Kabbinavar, 2003, Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer, J Clin Oncol, 21, 60, 10.1200/JCO.2003.10.066 · DOI · Paper page
- Gruenberger, 2015, Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial, Ann Oncol, 26, 702, 10.1093/annonc/mdu580 · DOI · Paper page
- Hochster, 2007, Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity, J Clin Oncol, 25, 4028, 10.1200/JCO.2007.13.5251 · doi:10.1200/jco.2007.13.5251
- Van Cutsem, 2001, Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study, J Clin Oncol, 19, 4097, 10.1200/JCO.2001.19.21.4097 · DOI · Paper page
- Alberts, 2005, Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study, J Clin Oncol, 23, 9243, 10.1200/JCO.2005.07.740 · DOI · Paper page
- Tejpar, 2012, Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab, J Clin Oncol, 30, 3570, 10.1200/JCO.2012.42.2592 · DOI · Paper page
- Loupakis, 2014, Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer, N Engl J Med, 371, 1609, 10.1056/NEJMoa1403108 · DOI · Paper page
- Peeters, 2015, Analysis of KRAS/NRAS mutations in a phase 3 study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment of metastatic colorectal cancer, Clin Cancer Res, 21, 5469, 10.1158/1078-0432.CCR-15-0526 · DOI · Paper page
- Van Cutsem, 2012, Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen, J Clin Oncol, 30, 3499, 10.1200/JCO.2012.42.8201 · DOI · Paper page
- Buchler, 2014, Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis, BMC Cancer, 14, 323, 10.1186/1471-2407-14-323 · doi:10.1186/1471-2407-14-323
- Cui, 2015, Neoadjuvant chemotherapy (NCT) plus targeted agents versus NCT alone in colorectal liver metastases patients: A systematic review and meta-analysis, Oncotarget, 6, 44005, 10.18632/oncotarget.5875 · DOI
- Sul, 2016, FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1, Oncologist, 21, 643, 10.1634/theoncologist.2015-0498 · DOI · Paper page
- Chen, 2014, BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis, PLoS One, 9, e90607, 10.1371/journal.pone.0090607 · DOI · Paper page
- Shankaran, 2018, Cost-effectiveness of cetuximab as first-line treatment for metastatic colorectal cancer in the United States, Am J Clin Oncol, 41, 65, 10.1097/COC.0000000000000231 · DOI
- Hong, 2020, Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials, Lancet Oncol, 21, 531, 10.1016/S1470-2045(19)30856-3 · DOI · Paper page
- Mitry, 2008, Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials, J Clin Oncol, 26, 4906, 10.1200/JCO.2008.17.3781 · DOI · Paper page
- Sartore-Bianchi, 2019, HER2 positivity predicts unresponsiveness to EGFR-targeted treatment in metastatic colorectal cancer, Oncologist, 24, 1395, 10.1634/theoncologist.2018-0785 · DOI · Paper page
- Wen, 2013, Ca/Mg infusions for the prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer: a meta-analysis, Ann Oncol, 24, 171, 10.1093/annonc/mds211 · DOI
- Porschen, 2007, Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group, J Clin Oncol, 25, 4217, 10.1200/JCO.2006.09.2684 · DOI · Paper page
- Peeters, 2014, Final results from a randomized phase 3 study of FOLFIRI +/- panitumumab for second-line treatment of metastatic colorectal cancer, Ann Oncol, 25, 107, 10.1093/annonc/mdt523 · DOI · Paper page
- Sobrero, 2009, Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer, Oncology, 77, 113, 10.1159/000229787 · DOI
- Hofheinz, Treatment with antiangiogenic drugs in multiple lines in patients with metastatic colorectal cancer: meta-analysis of randomized trials [published online August 30, 2016], Gastroenterol Res Pract
- Segelov, 2016, Response to cetuximab with or without irinotecan in patients with refractory metastatic colorectal cancer harboring the KRAS G13D mutation: Australasian Gastro-Intestinal Trials Group ICECREAM study, J Clin Oncol, 34, 2258, 10.1200/JCO.2015.65.6843 · DOI
- Price, 2015, Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer, Br J Cancer, 112, 963, 10.1038/bjc.2015.37 · DOI · Paper page
- Meric-Bernstam, 2019, Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study, Lancet Oncol, 20, 518, 10.1016/S1470-2045(18)30904-5 · DOI · Paper page
- Wang, 2015, Right-sided colon cancer and left-sided colorectal cancers respond differently to cetuximab, Chin J Cancer, 34, 384, 10.1186/s40880-015-0022-x · DOI
- Yoshino, 2012, TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial, Lancet Oncol, 13, 993, 10.1016/S1470-2045(12)70345-5 · DOI · Paper page
- Fujii, 2019, Bevacizumab in combination with TAS-102 improves clinical outcomes in patients with refractory metastatic colorectal cancer: a retrospective study [published online November 20, 2019], Oncologist
- Aparicio, 2016, Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02), Ann Oncol, 27, 121, 10.1093/annonc/mdv491 · DOI
- Douillard, 2013, Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer, N Engl J Med, 369, 1023, 10.1056/NEJMoa1305275 · DOI · Paper page
- Hartmann, 2012, Is there a difference in demography and clinical characteristics in patients treated with and without bevacizumab?, J Clin Oncol, 30, 3317, 10.1200/JCO.2012.43.3409 · doi:10.1200/jco.2012.43.3409
- Lewis, 2016, Programmed death-1 inhibition in cancer with a focus on non-small cell lung cancer: rationale, nursing implications, and patient management strategies, Clin J Oncol Nurs, 20, 319, 10.1188/16.CJON.319-326 · DOI
- Price, 2016, Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer, Eur J Cancer, 68, 51, 10.1016/j.ejca.2016.08.010 · DOI
- 2019, Drug Administration Package Insert MVASI bevacizumab awwb injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17
- Besora, 2018, Rechallenge with oxaliplatin and peripheral neuropathy in colorectal cancer patients, J Cancer Res Clin Oncol, 144, 1793, 10.1007/s00432-018-2691-8 · doi:10.1007/s00432-018-2691-8
- Segelov, 2014, The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials, Br J Cancer, 111, 1122, 10.1038/bjc.2014.404 · DOI
- XELODA, 2019, Drug Administration Package Insert capecitabine tablets for oral use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 020896
- XELODA, 2019, Drug Administration Package Insert capecitabine tablets for oral use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 020896
- O’Dwyer, 2006, Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy, J Clin Oncol, 24, 4534, 10.1200/JCO.2006.07.3031 · DOI · Paper page
- 2019, Drug Administration Package Insert OGIVRI trastuzumab dkst for injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17
- Sobrero, 2008, EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer, J Clin Oncol, 26, 2311, 10.1200/JCO.2007.13.1193 · DOI · Paper page
- Mauri, 2019, Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: systematic review of different strategies, Cancer Treat Rev, 73, 41, 10.1016/j.ctrv.2018.12.006 · DOI
- Hartmann, 2012, Is there a difference in demography and clinical characteristics in patients treated with and without bevacizumab?, J Clin Oncol, 30, 3317, 10.1200/JCO.2012.43.3409 · doi:10.1200/jco.2012.43.3409
200 of 374 shown
Cited by
Trifluridine–tipiracil and bevacizumab in refractory metastatic colorectal cancer
Prager, G. W., Taieb, J., Fakih, M., Ciardiello, F., Van Cutsem, E., Elez, E., Cruz, F. M., Wyrwicz, L., Stroyakovskiy, D., Pápai, Z., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2214963 · Cited by 467
Li, W., Zhou, C., Yu, L., Hou, Z., Liu, H., Kong, L., Xu, Y., He, J., Lan, J., Ou, Q., et al. (2024) · Autophagy · doi:10.1080/15548627.2023.2249762 · Cited by 461
Eng, C., Yoshino, T., Ruíz-García, E., Mostafa, N., Cann, C. G., O'Brian, B., Benny, A., Perez, R. O., & Cremolini, C. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00360-x · Cited by 449
Zhong, X., He, X., Wang, Y., Hu, Z., Huang, H., Zhao, S., Wei, P., & Li, D. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01358-5 · Cited by 329
Yu, Y., He, Z., Ouyang, J., Tan, Y., Chen, Y., Gu, Y., Mao, L., Ren, W., Wang, J., Lin, L., et al. (2021) · eBioMedicine · doi:10.1016/j.ebiom.2021.103460 · Cited by 280
Self-citation
Metadata
- Authors
- Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Farkas, L., Garrido-Laguna, I., Grem, J. L., Gunn, A., Hecht, J. R., Hoffe, S., Hubbard, J., Hunt, S., Johung, K. L., Kirilcuk, N., Krishnamurthi, S., Messersmith, W. A., Meyerhardt, J., Miller, E. D., Mulcahy, M. F., Nurkin, S., Overman, M. J., Parikh, A., Patel, H., Pedersen, K., Saltz, L., Schneider, C., Shibata, D., Skibber, J. M., Sofocleous, C. T., Stoffel, E. M., Stotsky-Himelfarb, E., Willett, C. G., Gregory, K. M., & Gurski, L. A.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2021-03
- Volume
- 19
- Issue
- 3
- Pages
- 329-359
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W3134887329
- Cited by
- 1,696
- References
- 292
- FWCI
- 103.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.